BNP Paribas Exane analyst Kirsty Ross-Stewart initiated coverage of Zealand Pharma (ZLDPF) with an Outperform rating and DKK 905 price target While timing “may be debated,” the attractive risk-reward is “difficult to ignore” at current levels, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZLDPF:
- Zealand Pharma price target lowered to DKK 850 from DKK 1,050 at Berenberg
- Zealand Pharma announces results from 28-week Phase 1b trial of dapiglutide
- Zealand Pharma appoints Johnson as Chief Development Officer
- Zealand Pharma’s Earnings Call: Growth Amid Challenges
- Zealand Pharma’s Strategic Partnership Fuels Growth